PepGen Inc. (NASDAQ:PEPG) SVP Niels Svenstrup Sells 10,000 Shares

PepGen Inc. (NASDAQ:PEPG) SVP Niels Svenstrup sold 10,000 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $13.41, for a total transaction of $134,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

PepGen Stock Down 3.6 %

PepGen stock opened at $13.16 on Friday. The business’s fifty day moving average is $13.16 and its 200 day moving average is $10.13. PepGen Inc. has a one year low of $3.72 and a one year high of $17.51.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.19. As a group, research analysts anticipate that PepGen Inc. will post -2.96 EPS for the current year.

Institutional Investors Weigh In On PepGen

Several large investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new position in shares of PepGen during the first quarter valued at approximately $30,000. Allspring Global Investments Holdings LLC bought a new stake in shares of PepGen in the third quarter valued at about $33,000. Rathbones Group PLC purchased a new stake in shares of PepGen in the 3rd quarter worth approximately $315,000. Artal Group S.A. bought a new stake in PepGen during the 1st quarter valued at $2,940,000. Finally, Adage Capital Partners GP L.L.C. boosted its position in PepGen by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock valued at $3,454,000 after purchasing an additional 105,000 shares in the last quarter. Institutional investors own 58.01% of the company’s stock.

Analysts Set New Price Targets

PEPG has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price target on shares of PepGen in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of PepGen in a research note on Wednesday.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.